Akeso
153
42
65
53
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.6%
7 terminated/withdrawn out of 153 trials
88.3%
+1.8% vs industry average
23%
35 trials in Phase 3/4
0%
0 of 53 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (153)
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
Role: lead
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
Role: lead
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Role: lead
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Role: lead
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Role: lead
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Role: lead
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis
Role: lead
Phase III Study of AK112 for NSCLC Patients
Role: collaborator
A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
Role: lead
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Role: lead
A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis
Role: lead
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Role: lead
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Role: lead
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
Role: lead
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Role: lead
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Role: lead
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Role: lead
AK112 in Advanced Non-Small Cell Lung Cancer
Role: lead
A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects
Role: lead
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Role: collaborator